| Nov 6 |
Coya Therapeutics GAAP EPS of -$0.26
|
| Nov 6 |
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Third Quarter 2024 Financial Results
|
| Nov 1 |
Coya Therapeutics names Arun Swaminathan as CEO
|
| Nov 1 |
Coya Therapeutics Announces Arun Swaminathan, Ph.D. Assumes New Role as Chief Executive Officer
|
| Oct 31 |
Coya Therapeutics: Buying The Dip After Unwarranted Sell-Off
|
| Oct 30 |
Coya Therapeutics Reports Positive Phase 2 Alzheimer’s Trial Results
|
| Oct 29 |
Coya Therapeutics' High-Dose Interleukin-2 Misses The Mark In Mid-Stage Alzheimer's Study
|
| Oct 29 |
Coya stock tumbles 23% on mixed results from Alzheimer's study
|
| Oct 29 |
Coya Therapeutics Announces Positive Results of a Double-Blind Study of Subcutaneous Low-Dose Interleukin-2 (LD IL-2) in Alzheimer’s Disease (AD) Presented at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid (Spain)
|
| Oct 28 |
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
|
